BAUSCH + LOMB CORP'S US SHARES FALL 3.9% IN LATE TRADE AFTER PHASE 2 STUDY RESULTS OF POST-SURGICAL OCULAR PAIN TREATMENT
BAUSCH + LOMB CORP'S US SHARES FALL 3.9% IN LATE TRADE AFTER PHASE 2 STUDY RESULTS OF POST-SURGICAL
BAUSCH + LOMB CORP'S US SHARES FALL 3.9% IN LATE TRADE AFTER PHASE 2 STUDY RESULTS OF POST-SURGICAL